Abstract:For the last decade, evolutionary forecasting models have influenced seasonal influenza vaccine design. These models attempt to predict which genetic variants circulating at the time of vaccine strain selection will be dominant 12 months later in the influenza season targeted by vaccination campaign. Forecasting models depend on hemagglutinin (HA) sequences from the WHO's Global Influenza Surveillance and Response System to identify currently circulating groups of related strains (clades) and estimate clade fitness for forecasts. However, the average lag between collection of a clinical sample and the submission of its sequence to the Global Initiative on Sharing All Influenza Data (GISAID) EpiFlu database is ~3 months. Submission lags complicate the already difficult 12-month forecasting problem by reducing understanding of current clade frequencies at the time of forecasting. These constraints of a 12-month forecast horizon and 3-month average submission lags create an upper bound on the accuracy of any long-term forecasting model. The global response to the SARS-CoV-2 pandemic revealed that modern vaccine technology like mRNA vaccines can reduce how far we need to forecast into the future to 6 months or less and that expanded support for sequencing can reduce submission lags to GISAID to 1 month on average. To determine whether these recent advances could also improve long-term forecasts for seasonal influenza, we quantified the effects of reducing forecast horizons and submission lags on the accuracy of forecasts for A/H3N2 populations. We found that reducing forecast horizons from 12 months to 6 or 3 months reduced average absolute forecasting errors to 25% and 50% of the 12-month average, respectively. Reducing submission lags provided little improvement to forecasting accuracy but decreased the uncertainty in current clade frequencies by 50%. These results show the potential to substantially improve the accuracy of existing influenza forecasting models by modernizing influenza vaccine development and increasing global sequencing capacity.

VaxSeer: Selecting influenza vaccines through evolutionary and antigenicity models

Models for predicting the evolution of influenza to inform vaccine strain selection

Predictive evolutionary modelling for influenza virus by site-based dynamics of mutations

Modeling the Antigenic Evolution of Seasonal Influenza Viruses with PREDAC for Vaccine Strain Selection in the Season of 2025

Projecting influenza vaccine effectiveness: A simulation study

Prediction of influenza vaccine effectiveness for the influenza season 2017/18 in the US

Multi-strain modeling of influenza vaccine effectiveness in older adults and its dependence on antigenic distance

Timely vaccine strain selection and genomic surveillance improves evolutionary forecast accuracy of seasonal influenza A/H3N2

Prediction of Influenza B Vaccine Effectiveness from Sequence Data

Leveraging baseline transcriptional features and information from single-cell data to power the prediction of influenza vaccine response

Leveraging Pre-Vaccination Antibody Titers across Multiple Influenza H3N2 Variants to Forecast the Post-Vaccination Response

The Potential Benefits of Delaying Seasonal Influenza Vaccine Selections for the Northern Hemisphere: A Retrospective Modeling Study in the United States

Evolutionary Non-Linear Modelling for Selecting Vaccines Against Antigenically Variable Viruses.

Computer-assisted vaccine design

A Novel Sequence-Based Antigenic Distance Measure for H1N1, with Application to Vaccine Effectiveness and the Selection of Vaccine Strains

Predicting the Mutating Distribution at Antigenic Sites of the Influenza Virus.

Predicting Influenza H3N2 Vaccine Efficacy From Evolution of the Dominant Epitope

Influenza Virus Vaccine Efficacy Based On Conserved Sequence Alignment

Concepts and methods for predicting viral evolution

An adaptive weight ensemble approach to forecast influenza activity in an irregular seasonality context

Estimating Waning of Vaccine Effectiveness: a Simulation Study